Bayer’s Stock Hovers at a Critical Technical Level as CEO Flags Hormuz and Legal Risks

Bayer stock hovers near 200-day moving average as US Supreme Court glyphosate ruling and Strait of Hormuz threat loom; Q1 revenue up 4.1% but free cash flow deeply negative.

Bayer shares ended the session at €35.95, a slim 1.58 percent advance from Friday’s close, but the recovery masks a precarious underlying picture. The stock is perched just 15 cents above its 200-day moving average of €35.80 — a level that has already been tested and briefly breached earlier in June. While the swift rebound above that line is technically encouraging, the margin is razor-thin, and any fresh slip below it would darken the chart outlook considerably.

Further up, the 50-day and 100-day averages at €38.39 and €40.50 respectively loom as resilient resistance ceilings. The 52-week high of €49.93, set in February, now sits a full 28 percent higher, underscoring the distance still needed for a meaningful recovery. The relative strength index stands at 42.6, a neutral-to-slightly-bearish reading that offers no clear directional signal. Meanwhile, annualized 30-day volatility of nearly 37 percent remains unusually elevated for a DAX constituent, reflecting the deep uncertainty that investors are pricing in.

That uncertainty stems from two distinct but equally menacing fronts. The first is legal. The US Supreme Court is deliberating the “Durnell” case, which will decide whether a company can be held liable under state law when a federal agency — in this case the Environmental Protection Agency — has deemed a product safe. A favorable ruling would effectively invalidate a substantial portion of the roughly 65,000 pending glyphosate claims. A negative outcome would keep the litigation mill turning. The decision is expected before the end of June.

Adding to the legal calendar, a final settlement hearing in Missouri is set for July 9. That court will decide whether to grant final approval to the $7.25 billion deal Bayer reached to resolve future glyphosate claims. CEO Bill Anderson has already cautioned that the evaluation of opt-out numbers could take “several more weeks,” dashing hopes for a quick resolution.

The second front is geopolitical. In an interview with t-online, Anderson warned that a blockade of the Strait of Hormuz could trigger a cascade of problems for Bayer’s agricultural business. While the company does not produce fertilizer itself, roughly one-third of global nitrogen-based fertilizer trade passes through the chokepoint. If the waterway remains blocked, Anderson said, harvests in the Northern Hemisphere could shrink significantly as early as autumn. The knock-on effect for Bayer: farmers facing lower yields would buy less seed and crop protection products. A shortage of corn-based animal feed could also push up meat and egg prices.

Amid these twin threats, Bayer’s underlying operational performance remains solid. First-quarter 2026 revenue rose 4.1 percent on a currency- and portfolio-adjusted basis to €13.4 billion, while adjusted EBITDA climbed 9 percent. Earnings per share exceeded expectations. The free cash flow picture, however, is ugly: a negative €2.32 billion, largely driven by higher outflows to resolve legal disputes, particularly over PCBs and glyphosate. Cash that might otherwise fund research or growth is being funneled into court settlements.

Anderson used the same interview to deliver a blistering assessment of Germany’s competitiveness, calling it a “massive location disadvantage” plagued by high non-wage labor costs, excessive bureaucracy and energy prices that are more than triple those on the Texas Gulf Coast and more than double those in China. “I have been here for three years and it simply is not getting any better,” he said, though he carefully noted that Chancellor Friedrich Merz is competent. He called for a “Mission for Germany,” insisting that German inventiveness is only sleeping, not dead.

With the Supreme Court ruling days or weeks away and the Hormuz blockade threat adding a geopolitical layer to an already fraught risk profile, Bayer’s stock is left balancing on a technical fulcrum at €35.80. The next few weeks will determine whether that support holds, or whether it gives way just as a potentially market-moving decision arrives from Washington.